Yazen Care-First Revenue Model

This is really a trust and compliance strategy disguised as pricing. By charging one monthly fee for care, coaching, labs, and the app, while leaving the drug purchase with outside pharmacies, Yazen makes the recurring product the medical program rather than the prescription itself. That matters in obesity telehealth, where regulators are watching for businesses that look like fast medication funnels, and where long term retention depends on patients feeling they are in a supervised care plan, not just buying injections.

• Yazen’s workflow is built to look and operate like a clinic. Patients start with screening, nurse consultation, blood work, physician review, and ongoing access to coaches and specialists. Medication is then filled by partner pharmacies at separate retail pricing. That separation helps show the company is selling care delivery, not just drug volume.
  1 sacra 2 sacra 5 yazen
• The tradeoff is lower direct capture of pharmacy margin than a vertically integrated model like Numan, which owns the clinical platform and pharmacy and bundles medication into subscription packages. Yazen gives up some unit economics, but gains a cleaner regulatory posture and a more credible medical brand for employers and insurers.
  1 sacra 3 sacra 6 sacra
• That distinction is especially important because UK regulators have been actively policing weight loss prescription drug advertising, and Yazen was already the subject of an upheld ASA ruling in July 2025 over public promotion of weight loss medication. In that environment, a care first revenue model is not optional branding, it is operating infrastructure.
  4 asa 7 asa 8 asa

The next step is to turn this compliant care model into a broader obesity management platform. If Yazen keeps proving retention, outcomes, and lower total treatment cost through careful dosing and maintenance programs, the same structure should travel well into employer benefits, insurer coverage, and deeper metabolic care across Europe.